Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) announced strategic collaborations with Viz.ai and the American Heart Association aimed at improving diagnosis and care coordination for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).

The partnership with Viz.ai involves developing an AI-enabled ATTR-CM care pathway that combines FDA-cleared echocardiography AI algorithm Us2.ai with electronic health record connectivity. The collaboration includes the AWARE study, a multi-system prospective implementation study designed to evaluate AI-enabled screening integration into clinical workflows. The initiative will launch at five pilot health systems later this year.

Separately, Alnylam is supporting a three-year American Heart Association initiative that will convene a 10-site cohort of multidisciplinary health systems in a national learning collaborative. The program aims to identify care gaps, share practices, and scale models for diagnosing and managing ATTR-CM.

ATTR-CM is a progressive heart failure condition that remains underdiagnosed. The disease affects an estimated 350,000 people worldwide, with approximately 80% remaining undiagnosed, according to the press release.

"Earlier recognition can fundamentally change a patient's course of disease," said Sameer Bansilal, Vice President, Global TTR Medical Lead at Alnylam Pharmaceuticals.

Tim Showalter, Chief Medical Officer at Viz.ai, stated that the collaboration focuses on "closing the gap between the first clinical signal and meaningful clinical action."

Alnylam hosted a TTR investor webinar to discuss these initiatives. The company specializes in RNA interference therapeutics and has six approved medicines available in more than 70 countries.